A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
NCT06678269
This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to test different doses of abemaciclib to find the best dose in participants while receiving hormone therapy and radiation therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Breast Cancer
- Stage IV Breast Cancer
- Breast Cancer
- Breast Cancer Stage IV
- Breast Cancer Metastatic
- HER2-negative Breast Cancer
- HER2 Negative Breast Carcinoma
- Hormone-receptor-positive Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- May 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 3
- Memorial Sloan Kettering at Basking Ridge (All protocol activities) · Basking Ridge, NJ
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, NJ
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, NJ
New York · 4
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) · Commack, NY
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, NY
- Memorial Sloan Kettering Cancer Center (All protocol activites) · New York, NY
- Memorial Sloan Kettering Nassau (All protocol activities) · Rockville Centre, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.